Chapter 5 of 25
What you will learn
- Recognize common histological names.
- Separate grade from stage and molecular group.
- Understand why specialist pathology review may change a plan.
Endometrioid carcinoma and grade
Endometrioid carcinoma resembles glands of the normal endometrium and is the most common type. For this histology, grades 1 and 2 are generally grouped as low grade and grade 3 as high grade. Grading considers how much of the tumour forms glands versus solid areas and also assesses concerning nuclear features. Grade is not a countdown or a description of how long the cancer has been present.
A low-grade cancer can still spread, and a high-grade cancer can be confined to the uterus. Grade 3 endometrioid cancers are biologically diverse: a pathogenic POLE mutation may identify a favourable early-stage group, while p53-abnormal disease can carry a different risk. This is one reason molecular classification is particularly useful when morphology alone leaves uncertainty.
Less common histologies
| Histology | Patient-friendly explanation |
|---|---|
| Serous carcinoma | An aggressive epithelial type, often p53-abnormal; spread can occur despite limited uterine invasion |
| Clear cell carcinoma | A distinctive less common type requiring careful pathological confirmation |
| Carcinosarcoma | A carcinoma with both epithelial and sarcoma-like components; treated as an aggressive endometrial carcinoma |
| Undifferentiated carcinoma | Cells have lost recognizable glandular features |
| Dedifferentiated carcinoma | A differentiated component occurs with an undifferentiated component |
| Mixed carcinoma | More than one histological component is present |
Rare tumours may need additional stains and review by a gynaecological pathologist. Carcinosarcoma should not be confused with a pure uterine sarcoma such as leiomyosarcoma. Their names can sound similar while their staging and evidence base differ. A report describing a “high-grade malignancy” may be provisional until additional tests are complete.
What histology changes
Certain aggressive types prompt more extensive evaluation for extrauterine disease, different surgical staging considerations and a greater likelihood of systemic treatment. HER2 testing can be relevant in particular advanced or recurrent cancers, especially serous carcinoma. Histology can also affect eligibility for a clinical trial: not every study included carcinosarcoma or all rare subtypes.
Treatment should not be chosen from a histology label alone. A small tumour without invasion, a tumour with substantial lymphovascular invasion and a cancer with distant spread have different contexts. Age, other illnesses, previous treatment and the patient's preferences remain important. If recommendations differ between centres, ask which risk feature is driving the disagreement.
Why a biopsy and hysterectomy report can differ
A small biopsy may not contain the highest-grade or rare component. Examination of the whole uterus can therefore refine the diagnosis or grade without meaning the first clinician made an error. Molecular tests may also return after the initial report. Ask whether the tumour board has reviewed the final integrated report rather than a preliminary version.
Older descriptions of “type I” and “type II” endometrial cancer may appear online. They are broad historical groupings and do not capture the modern four-group molecular classification. A tumour should not be assumed low risk simply because it is endometrioid or hormone-related.
Questions and take-home messages
Ask: What is the exact type and grade? Is expert review needed? Are MMR, p53 and POLE results available where they could change care? Was my subtype represented in the treatment trial being discussed? A meaningful explanation should connect those answers to your options, not just provide a list of technical labels.
Related chapters
- How Endometrial Cancer Is Diagnosed
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- WHO Classification of Female Genital Tumours, fifth edition, 2020
- Berek et al. FIGO staging of endometrial cancer, 2023
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- NCI: Endometrial Cancer Treatment PDQ
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy